eXoZymes Secures $2.02M NIH Grant for Cannabinoid Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2026
0mins
Source: seekingalpha
- Grant Amount: eXoZymes has received a Notice of Award from the NIH for a Phase IIB Small Business Innovation Research grant totaling $2.02 million, expected to commence on July 1, 2026, significantly bolstering its funding for cannabinoid and analog development.
- Research Focus: The grant will support eXoZymes' efforts to develop cannabinoids and engineered analogs designed for pharmaceutical evaluation, indicating the company's strategic positioning and innovative potential in the pharmaceutical sector.
- Market Outlook: As the application of cannabinoids in medicine becomes increasingly prevalent, this funding not only secures financial backing for eXoZymes but also enhances its competitive edge in the rapidly growing biopharmaceutical market.
- Financing Update: eXoZymes recently completed a public offering of stock and warrants totaling $5.33 million, further strengthening its capital base to support future research and market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EXOZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EXOZ
About EXOZ
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
eXoZymes Secures $2.02M NIH Grant for Cannabinoid Research
- Grant Amount: eXoZymes has received a Notice of Award from the NIH for a Phase IIB Small Business Innovation Research grant totaling $2.02 million, expected to commence on July 1, 2026, significantly bolstering its funding for cannabinoid and analog development.
- Research Focus: The grant will support eXoZymes' efforts to develop cannabinoids and engineered analogs designed for pharmaceutical evaluation, indicating the company's strategic positioning and innovative potential in the pharmaceutical sector.
- Market Outlook: As the application of cannabinoids in medicine becomes increasingly prevalent, this funding not only secures financial backing for eXoZymes but also enhances its competitive edge in the rapidly growing biopharmaceutical market.
- Financing Update: eXoZymes recently completed a public offering of stock and warrants totaling $5.33 million, further strengthening its capital base to support future research and market expansion.
See More
eXoZymes Prices Public Offering to Raise $5.33 Million
- Offering Details: eXoZymes priced a public offering of 296,135 units at $18 each, with each unit comprising 2 common shares and 1 warrant, expected to generate approximately $5.33 million, indicating the company's ability to raise capital in the market.
- Warrant Terms: Each warrant becomes exercisable one year after issuance at an exercise price of $11.24 per share, providing investors with potential future value while also supporting the company's future funding needs.
- Use of Proceeds: The proceeds will be utilized to advance the company's N-trans-caffeoyltyramine platform, support R&D, develop future products, and fund general corporate and working capital needs, demonstrating the company's focus on future growth.
- Market Reaction: Following the public offering announcement, eXoZymes shares fell 5.5% in premarket trading, reflecting a cautious market sentiment regarding the offering, which may impact investor confidence.
See More
MDB Capital Holdings Earnings Outlook
- Proven IPO Model: MDB Capital Holdings LLC (NASDAQ:MDBH) has successfully launched 18 IPOs, demonstrating its strong capabilities in the microcap market, although the current market conditions are challenging, its model still holds potential to attract investors.
- AI-Driven Due Diligence: The company is leveraging artificial intelligence to potentially reduce due diligence and company preparation time by two-thirds, which not only enhances efficiency but may also accelerate the launch of new companies, thereby diversifying and increasing the potential returns of its investment portfolio.
- Investment in Distinct Assets: MDBH is investing in unique assets like MDB Direct and PatentVest, which possess independent market value and are expected to achieve higher valuations through spin-offs, further enhancing the company's overall financial performance.
- Macroeconomic Uncertainty: Despite the company's advantages in assets and technology, uncertainties in the macroeconomic environment and internal execution risks could impact its future business development and investment returns, necessitating vigilance from investors.
See More
EXoZymes Inc Earnings Report Analysis and Outlook
- Financial Overview: As of the end of 2025, EXoZymes Inc reported cash and cash equivalents of $3.04 million, while total operating expenses reached $9.72 million for the year, an increase of $3.78 million from 2024, resulting in a net loss of $9.16 million, indicating financial strain on the company.
- Technological Advancements: The company has successfully developed a breakthrough cell-free biomanufacturing platform that enables the rapid and cost-effective production of rare, high-value molecules, which not only enhances production efficiency but also lays the groundwork for future market entry and potential partnerships.
- Market Challenges: As a pre-revenue company, EXoZymes faces skepticism from investors and partners, particularly due to past disappointments in the synthetic biology sector, which could hinder its ability to secure favorable licensing terms and increase uncertainty about future growth.
- Strategic Direction: The company plans to support operations through fundraising while focusing on business opportunities in NCT and cannabinoids, with human use studies expected in 2025; however, the lack of clear milestones and timelines necessitates stronger collaboration with contract manufacturers to ensure supply chain robustness.
See More
eXoZymes Reports Increased FY Net Loss and Rising Expenses
- Annual Net Loss: eXoZymes reported a net loss of $9.16 million for FY 2025, a significant increase from the $5.86 million loss in 2024, indicating ongoing challenges in achieving profitability.
- Rising Operating Expenses: Operating expenses surged to $9.72 million in 2025, up from $5.93 million in the previous year, primarily due to targeted investments in R&D and product development, highlighting the company's focus on future growth.
- Cash Position: By the end of 2025, eXoZymes had $3.04 million in cash and cash equivalents, which is expected to support the execution of key programs through mid-Q2 2026, ensuring operational continuity.
- Strategic Investment Focus: Despite the losses, eXoZymes is increasing its investment in R&D, aiming to drive future product development and enhance market competitiveness, demonstrating the company's commitment to long-term growth.
See More
Monday 7/7 Insider Buying Report: EXOZ, IAF
Insider Purchases: CEO Michael Heltzen of Exozymes purchased 1,040 shares at $10.22 each, while Director Moritz A. Sell bought $9,000 worth of Aberdeen Australia Equity Fund shares at $4.50 each, marking their first purchases in the past year.
Stock Performance: Exozymes stock is currently trading lower than Heltzen's purchase price, while Aberdeen Australia Equity Fund has seen a slight decline of 0.9% on the same day.
See More
eXoZymes Secures $2.02M NIH Grant for Cannabinoid Research
- Grant Amount: eXoZymes has received a Notice of Award from the NIH for a Phase IIB Small Business Innovation Research grant totaling $2.02 million, expected to commence on July 1, 2026, significantly bolstering its funding for cannabinoid and analog development.
- Research Focus: The grant will support eXoZymes' efforts to develop cannabinoids and engineered analogs designed for pharmaceutical evaluation, indicating the company's strategic positioning and innovative potential in the pharmaceutical sector.
- Market Outlook: As the application of cannabinoids in medicine becomes increasingly prevalent, this funding not only secures financial backing for eXoZymes but also enhances its competitive edge in the rapidly growing biopharmaceutical market.
- Financing Update: eXoZymes recently completed a public offering of stock and warrants totaling $5.33 million, further strengthening its capital base to support future research and market expansion.
See More
eXoZymes Prices Public Offering to Raise $5.33 Million
- Offering Details: eXoZymes priced a public offering of 296,135 units at $18 each, with each unit comprising 2 common shares and 1 warrant, expected to generate approximately $5.33 million, indicating the company's ability to raise capital in the market.
- Warrant Terms: Each warrant becomes exercisable one year after issuance at an exercise price of $11.24 per share, providing investors with potential future value while also supporting the company's future funding needs.
- Use of Proceeds: The proceeds will be utilized to advance the company's N-trans-caffeoyltyramine platform, support R&D, develop future products, and fund general corporate and working capital needs, demonstrating the company's focus on future growth.
- Market Reaction: Following the public offering announcement, eXoZymes shares fell 5.5% in premarket trading, reflecting a cautious market sentiment regarding the offering, which may impact investor confidence.
See More
MDB Capital Holdings Earnings Outlook
- Proven IPO Model: MDB Capital Holdings LLC (NASDAQ:MDBH) has successfully launched 18 IPOs, demonstrating its strong capabilities in the microcap market, although the current market conditions are challenging, its model still holds potential to attract investors.
- AI-Driven Due Diligence: The company is leveraging artificial intelligence to potentially reduce due diligence and company preparation time by two-thirds, which not only enhances efficiency but may also accelerate the launch of new companies, thereby diversifying and increasing the potential returns of its investment portfolio.
- Investment in Distinct Assets: MDBH is investing in unique assets like MDB Direct and PatentVest, which possess independent market value and are expected to achieve higher valuations through spin-offs, further enhancing the company's overall financial performance.
- Macroeconomic Uncertainty: Despite the company's advantages in assets and technology, uncertainties in the macroeconomic environment and internal execution risks could impact its future business development and investment returns, necessitating vigilance from investors.
See More
EXoZymes Inc Earnings Report Analysis and Outlook
- Financial Overview: As of the end of 2025, EXoZymes Inc reported cash and cash equivalents of $3.04 million, while total operating expenses reached $9.72 million for the year, an increase of $3.78 million from 2024, resulting in a net loss of $9.16 million, indicating financial strain on the company.
- Technological Advancements: The company has successfully developed a breakthrough cell-free biomanufacturing platform that enables the rapid and cost-effective production of rare, high-value molecules, which not only enhances production efficiency but also lays the groundwork for future market entry and potential partnerships.
- Market Challenges: As a pre-revenue company, EXoZymes faces skepticism from investors and partners, particularly due to past disappointments in the synthetic biology sector, which could hinder its ability to secure favorable licensing terms and increase uncertainty about future growth.
- Strategic Direction: The company plans to support operations through fundraising while focusing on business opportunities in NCT and cannabinoids, with human use studies expected in 2025; however, the lack of clear milestones and timelines necessitates stronger collaboration with contract manufacturers to ensure supply chain robustness.
See More
eXoZymes Reports Increased FY Net Loss and Rising Expenses
- Annual Net Loss: eXoZymes reported a net loss of $9.16 million for FY 2025, a significant increase from the $5.86 million loss in 2024, indicating ongoing challenges in achieving profitability.
- Rising Operating Expenses: Operating expenses surged to $9.72 million in 2025, up from $5.93 million in the previous year, primarily due to targeted investments in R&D and product development, highlighting the company's focus on future growth.
- Cash Position: By the end of 2025, eXoZymes had $3.04 million in cash and cash equivalents, which is expected to support the execution of key programs through mid-Q2 2026, ensuring operational continuity.
- Strategic Investment Focus: Despite the losses, eXoZymes is increasing its investment in R&D, aiming to drive future product development and enhance market competitiveness, demonstrating the company's commitment to long-term growth.
See More
Monday 7/7 Insider Buying Report: EXOZ, IAF
Insider Purchases: CEO Michael Heltzen of Exozymes purchased 1,040 shares at $10.22 each, while Director Moritz A. Sell bought $9,000 worth of Aberdeen Australia Equity Fund shares at $4.50 each, marking their first purchases in the past year.
Stock Performance: Exozymes stock is currently trading lower than Heltzen's purchase price, while Aberdeen Australia Equity Fund has seen a slight decline of 0.9% on the same day.
See More
